CTLT
Catalent, Inc.
Set alert
63.48 0.00 0.00%
63.44 Day range 63.50
52-week range unavailable
- Open
- 63.49
- Prev close
- 63.48
- Mkt cap
- 11.52B
- Vol
- 13.67M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 63.44
- High
- 63.50
- Earnings
- Nov 5, 2024
Next earnings
Nov 5, 2024
Expected Nov 5, 2024. Consensus EPS estimate 0.11.
Financials — quick view
CTLT Revenue — quarterly 1.02B
CTLT Net income — quarterly -129.00M
CTLT EPS — quarterly -0.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | 0.11 | — | — | — |
| Aug 29, 2024 | Jun 1, 2024 | 0.46 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.24 | — | — | — |
| Aug 29, 2023 | Jun 1, 2023 | 0.10 | — | — | — |
News
- Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
- Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services
- Cartherics and Catalent Expand Commercial License Agreement
- Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
- SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
- Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
- Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Your note
Sign in to keep a note on CTLT — it syncs with the Stock Master app.